ABSTRACT
The prospects and problems of radioimmunodetection (RAID) are perhaps predicted by the experience with radiolabeled antibody therapy, or radioimmunotherapy. This chapter reviews the few RAID products approved in the United States, both from a historical perspective, as well as to emphasize that these need to be considered in their temporal setting. Once antibodies transverse the blood vessels into the tissue space, they generally bind with high affinity/avidity, which in turn determines their residence time in the tumor. In-hapten-peptide, tumor uptake reached similar levels, but tumor-nontumor ratios were significantly improved because the smaller construct also cleared from the normal tissues more efficiently. The bispecific antibody infusion could be performed by the patient’s oncologist, who would then coordinate this infusion with scheduling the injection of the radiolabeled hapten-peptide in a nuclear imaging facility. In medullary thyroid cancer, initial clinical results with a first-generation pretargeting method have shown evidence of improved survival.
